Major U.S. stock indexes closed mixed on Thursday, February 26, 2026, with technology shares under pressure even as broader cyclicals and small caps showed resilience. The session highlighted ongoing investor tension between enthusiasm for AI-driven growth and concern about stretched valuations and…
Nvidia’s latest quarter reads less like an earnings release and more like a balance sheet for the AI industrial revolution, with revenue, profits, and guidance all accelerating as if on GPU overclock.
Record Quarter: When “Blowout” Sounds Too Modest
Nvidia reported fourth-quarter…
US stocks extended this week’s rebound on Wednesday, February 25, 2026, with a tech-led advance ahead of and then through Nvidia’s blockbuster earnings release after the bell.finance.yahoo+5
Index performance
The S&P 500 rose about 0.8% to roughly 6,946, marking a second straight…
US stocks rebounded on Tuesday, February 24, 2026, with major indexes clawing back part of Monday’s AI-driven selloff as software and AI beneficiaries led a broad relief rally ahead of closely watched Nvidia earnings scheduled for tomorrow, Wednesday.
Index performance
The Dow Jones…
In Barcelona’s annual parade of buzzwords, Nokia (NOK) and Amazon Web Services (AMZN) (AWS) have managed to turn “network slicing” and “agentic AI” into headliners rather than footnotes. The duo is unveiling what they describe as an industry‑first: an intent‑based, agentic AI‑powered…
In a market that has spent three years asking whether iBuying is a feature or a business, Opendoor’s (OPEN) latest “Open House” suggests Opendoor 2.0 may finally be moving in. The company’s Q4 2025 results delivered faster growth in home acquisitions, improving…
Meta Platforms (META) has inked a multi‑year pact to buy up to 6 gigawatts of AMD Instinct GPUs, a supersized order that instantly puts AMD at the center of one of the largest AI infrastructure build‑outs on the planet. The scale of…
Tandem Diabetes Care’s (TNDM) latest trip to the capital markets reads less like a distress signal and more like a company quietly extending its runway in a race it fully intends to finish. At the same time, a familiar name in diabetes…
Summit Therapeutics’ (SMMT) latest tweak to its clinical playbook has turned what was already one of biotech’s higher‑stakes stories into something closer to appointment viewing for Wall Street.
A Phase 3 Trial Adds a Plot Twist
Summit now plans an interim progression‑free…
Taleb, Citrini and the Birth of the AI Scare Trade
Nassim Nicholas Taleb and Citrini Research have unintentionally become co-authors of Wall Street’s latest genre: the AI scare trade, where investors hedge against the possibility that the very technology powering the boom becomes…
